TAS::75 0849::TAS MULTIFUNCTIONAL NANOJACKETS FOR BREAST CANCER TREATMENT

Keystone Nano公司与纳尔科公司建立了成功的伙伴关系，并与强生公司、礼来公司、联合治疗公司、纳米疗法公司和美国国家癌症研究所共同开发计划，将开发多功能磷酸钙纳米夹克，用于同时诊断和治疗乳腺癌。尽管在检测和治疗方面取得了进展，乳腺癌仍然是女性中第二常见的癌症，女性在有生之年罹患乳腺癌的可能性估计为12%，每年有超过4万名女性死于乳腺癌(ACS)。开发的纳米夹克既包含FDA批准的用于基于荧光成像的诊断的近红外荧光团吲哚青绿，也包含针对PI3K基因突变的siRNA，该突变发生在大约25%的乳房中 癌症，将导致多功能纳米粒子药物，可以同时成像和治疗乳腺癌。该第一阶段项目的目标是演示可重复制造的 ICG-PI3KCA siRNA纳米夹克以及体内外对人乳腺癌的诊断和治疗效果。如果成功，这些数据将为目标的进一步开发奠定基础 ICG-PI3KCA siRNA纳米夹克，并为一系列治疗多种癌症的纳米夹克产品提供基础。

Keystone Nano, building on a successful partnership with Nalco and co-development programs with Johnson & Johnson, Eli Lilly, United Therapeutics, NanoTherapies, and the NCI, will develop multifunctional calcium phosphate NanoJackets for the simultaneous diagnosis and treatment of breast cancer. Despite advances in detection and treatment, breast cancer is still the second most common cancer among women with the chance of a woman developing breast cancer during her lifetime at an estimated 12% and over 40,000 women dying from breast cancer each year (ACS). The development of NanoJackets containing both Indocyanine Green, a FDA-approved near infrared fluorophore, for fluorescent imaging based diagnosis, as well as siRNA directed against a mutation in the PI3K gene, which occurs in approximately 25% of breast cancers, will result in a multifunctional nanoparticulate pharmaceutical that can simultaneously image and treat breast cancer. The objectives of this Phase I project are to demonstrate reproducible manufacturing of ICG-PI3KCA siRNA NanoJackets as well as in vitro and in vivo diagnostic and therapeutic efficacy for human breast cancer. If successful, these data will lay the groundwork for further development of targeted ICG-PI3KCA siRNA NanoJackets and provide the basis for an array of theranostic NanoJacket products for a variety of cancers.